康緣藥業(600557.SH):關於熱毒寧注射液對基孔肯雅熱的療效,公司目前正在廣東開展針對該適應症的臨牀研究
格隆匯8月6日丨康緣藥業(600557.SH)在互動平臺表示,公司獨家品種熱毒寧注射液於2005年獲得新藥證書,是國家醫保目錄品種,功能主治:清熱、疏風、解毒。用於外感風熱所致感冒、咳嗽,症見高熱、微惡風寒、頭痛身痛、咳嗽、痰黃;上呼吸道感染、急性支氣管炎見上述證候者。已完成的流感、手足口、新冠等RCT臨牀研究表明,與對照組相比,熱毒寧注射液能快速緩解病毒性感染疾病狀態,對發熱症狀,尤其對高熱病程療效突出,還可綜合改善患者呼吸急促、咳嗽、咽痛、鼻塞流涕等臨牀症狀,總有效率高;可調控炎症因子,有效減輕炎症反應,改善治療結局。 熱毒寧注射液治療登革熱療效確切,2014年完成的“熱毒寧注射液抗登革病毒基礎研究”顯示熱毒寧注射液具有較好的抗病毒活性;“熱毒寧注射液治療普通型登革熱的有效性及安全性臨牀研究”顯示,熱毒寧注射液治療後可顯著縮短髮熱緩解時間,提高白細胞、血小板轉正常率,提高痊癒率。熱毒寧注射液在《登革熱診療方案(2024年版)》等多項指南中被明確推薦。關於熱毒寧注射液對基孔肯雅熱的療效,公司目前正在廣東開展針對該適應症的臨牀研究。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.